NEW YORK, June 10 - Protein biochip company Zyomyx has tapped Robert Monaghan as its new CEO, the company said yesterday.
Monaghan replaces Lawrence Cohen, who has been CEO and president of the company since 2001. Cohen has been named vice chairman, and will continue to work full time at the Hayward, Calif.-based company.
Most recently, Monaghan served as president of Sigma Diagnostics, as well as its subsidiaries, and supervised the sale of the company in 2002. He also has served as a vice president of R&D at Dade Behring, vice president of sales at Behring Diagnostics, and in business development, marketing, and sales positions with SYVA, a division of Syntex pharmaceuticals; Ciba Corning Diagnostics, Health Charge Corporation, hospital finance consulting group Amherst Associates, group, and the American Hospital Supply Corporation.
Zyomyx's transition in leadership also reflects a change in strategy, executives said. The company is aiming to move toward of commercialization of its Protein Profiling Biochips.
"Based on customer feedback, Zyomyx will be focusing on the commercialization of products to facilitate therapeutic and diagnostic programs, with emphasis in inflammation, cardiovascular, and oncology, in line with the unique capabilities of our current protein biochip line and biochip products in our pipeline," Monaghan said in a statement.
The Protein Profiling chips are designed, like microarrays, to enable researchers to profile expression of 30 proteins in human serum samples at once. Currently, the company has a human cytokine profiling chip.
Monaghan has also been appointed to Zyomyx's board of directors.